BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 1515242)

  • 1. Toxicity of single-day high-dose vincristine, melphalan, etoposide and carboplatin consolidation with autologous bone marrow rescue in advanced neuroblastoma.
    Gordon SJ; Pearson AD; Reid MM; Craft AW
    Eur J Cancer; 1992; 28A(8-9):1319-23. PubMed ID: 1515242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma.
    Corbett R; Pinkerton R; Pritchard J; Meller S; Lewis I; Kingston J; McElwain T
    Eur J Cancer; 1992; 28A(8-9):1324-8. PubMed ID: 1515243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma.
    Hartmann O; Benhamou E; Beaujean F; Kalifa C; Lejars O; Patte C; Behard C; Flamant F; Thyss A; Deville A
    J Clin Oncol; 1987 Aug; 5(8):1205-11. PubMed ID: 3305792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tandem high-dose chemotherapy with autologous stem cell rescue for stage M high-risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens.
    Kato S; Kubota Y; Watanabe K; Hogetsu K; Arakawa Y; Koh K; Takita J; Hiwatari M
    Pediatr Transplant; 2020 Nov; 24(7):e13772. PubMed ID: 32543778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers.
    Elborai Y; Hafez H; Moussa EA; Hammad M; Hussein H; Lehmann L; Elhaddad A
    Pediatr Transplant; 2016 Mar; 20(2):284-9. PubMed ID: 26614402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
    Ozkaynak MF; Sahdev I; Gross TG; Levine JE; Cheerva AC; Richards MK; Rozans MK; Shaw PJ; Kadota RP
    J Pediatr Hematol Oncol; 2008 Mar; 30(3):204-9. PubMed ID: 18376282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
    Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
    Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fractionated total body irradiation, high-dose melphalan, etoposide, and carboplatin (FTBI-MEC) for autologous stem cell transplantation in children with advanced neuroblastoma and primitive neuroectodermal tumor.
    Emminger W; Gadner H
    Pediatr Hematol Oncol; 1992; 9(2):183-5. PubMed ID: 1356004
    [No Abstract]   [Full Text] [Related]  

  • 9. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study.
    Philip T; Ladenstein R; Zucker JM; Pinkerton R; Bouffet E; Louis D; Siegert W; Bernard JL; Frappaz D; Coze C
    Br J Cancer; 1993 Jan; 67(1):119-27. PubMed ID: 8427772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melphalan combined with a carboplatin dose based on glomerular filtration rate followed by autologous stem cell rescue for children with solid tumours.
    Shaw PJ; Pinkerton CR; Yaniv I
    Bone Marrow Transplant; 1996 Dec; 18(6):1043-7. PubMed ID: 8971371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose melphalan, etoposide, and carboplatin (MEC) +/- fractionated total body irradiation for treatment of advanced solid tumors.
    Gadner H; Emminger W; Ladenstein R; Peters C
    Pediatr Hematol Oncol; 1992; 9(2):v-viii. PubMed ID: 1524986
    [No Abstract]   [Full Text] [Related]  

  • 12. [131I]metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma.
    Corbett R; Pinkerton R; Tait D; Meller S
    J Nucl Biol Med (1991); 1991; 35(4):228-31. PubMed ID: 1823824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry. Italian Association of Pediatric Hematology-Oncology, BMT Group.
    Garaventa A; Rondelli R; Lanino E; Dallorso S; Dini G; Bonetti F; Arrighini A; Santoro N; Rossetti F; Miniero R; Andolina M; Amici A; Indolfi P; Lo Curto M; Favre C; Paolucci P; Pession A; De Bernardi B
    Bone Marrow Transplant; 1996 Jul; 18(1):125-30. PubMed ID: 8832005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
    Desai AV; Heneghan MB; Li Y; Bunin NJ; Grupp SA; Bagatell R; Seif AE
    Bone Marrow Transplant; 2016 Sep; 51(9):1204-10. PubMed ID: 27159174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors.
    Ozkaynak MF; Matthay K; Cairo M; Harris RE; Feig S; Reynolds CP; Buckley J; Villablanca JG; Seeger RC
    J Clin Oncol; 1998 Mar; 16(3):937-44. PubMed ID: 9508176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
    Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
    Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors.
    Wilson WH; Jain V; Bryant G; Cowan KH; Carter C; Cottler-Fox M; Goldspiel B; Steinberg SM; Longo DL; Wittes RE
    J Clin Oncol; 1992 Nov; 10(11):1712-22. PubMed ID: 1403054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin, and total-body irradiation.
    McCowage GB; Vowels MR; Shaw PJ; Lockwood L; Mameghan H
    J Clin Oncol; 1995 Nov; 13(11):2789-95. PubMed ID: 7595740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single or double consolidation treatment according to remission status after initial therapy in metastatic neuroblastoma: first results of LMCE 3 study in 40 patients.
    Zucker JM; Philip T; Bernard JL; Michon J; Bouffet E; Gentet JC; Lopez M; Coze C; Philip I
    Bone Marrow Transplant; 1991; 7 Suppl 2():91. PubMed ID: 1878739
    [No Abstract]   [Full Text] [Related]  

  • 20. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
    Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
    Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.